Business
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
QUEENSBURY, N.Y., January 09, 2026--Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results and business updates for the fourth quarter and year-ended December 31, 2025.
About this update from Delcath Systems, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/eba01ca2747b76b9d4f9ad1e2f32c9b8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Rm9PQHDFqxBv2vwhTg4rcQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/eba01ca2747b76b9d4f9ad1e2f32c9b8","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/DjguP6x0msTnUNJ3vs6l.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/eba01ca2747b76b9d4f9ad1e2f32c9b8","width":1024,"height":512}},"lazy":false},{"type":"text","content":"QUEENSBURY, N.Y., January 09, 2026--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results and business updates for the fourth quarter and year-ended December 31, 2025.","length":371,"tagName":"p"},{"type":"text","content":"Preliminary Fourth Quarter and Full-Year 2025 Financial Results (unaudited)","length":75,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total fourth quarter and full year revenue expected to be approximately $20.7 million and $85.2 million, respectively","length":117,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"HEPZATO KIT™ fourth quarter and full year revenue expected to be approximately $19.0 million and $78.8 million, respectively","length":124,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"CHEMOSAT® fourth quarter and full year revenue expected to be approximately $1.7 million and $6.4 million, respectively","length":119,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":243,"olType":false}]},{"val":[{"type":"text","content":"628,572 common shares repurchased for $6.0 million through December 31, 2025 under the approved $25.0 million Share Buyback Program","length":131,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"As of December 31, 2025, the Company had approximately $91.0 million of cash and short-term investments and no debt compared to cash and shor...